Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, drug interactions, dosage and administration, and place in therapy of atomoxetine in the treatment of attention-deficit ...

Brigham and Women’s Hospital scientists identified atomoxetine as a molecule that can counter the withdrawal of endogenous noradrenergic drive that is thought to lead to OSA during non-REM sleep.

(HealthDay)—Treatment with the selective noradrenalin-reuptake-inhibitor atomoxetine is not associated with increased suicide risk compared with stimulant use in children and adolescents ...

Strattera (atomoxetine) is an oral medication that healthcare providers may prescribe for attention deficit hyperactivity disorder (ADHD). This behavioral disorder can cause hyperactivity ...

Stimulants and atomoxetine had short-term benefits in adults with ADHD, but long-term efficacy remains under-investigated. Atomoxetine was less tolerable than placebo. In a large network meta ...

Atomoxetine has been approved by the FDA as the first new drug in 30 years for the treatment of attention deficit/hyperactivity disorder (ADHD). As a selective norepinephrine uptake inhibitor and ...

New Rochelle, NY, September 7, 2016--A new study shows significant improvement in critical components of reading, including decoding and vocabulary, among children treated with atomoxetine ...

Clinical trial data indicate that atomoxetine is safe and well tolerated for the treatment of ADHD; however, safety data about long-term use (greater than one year) are unavailable. Adverse events ...

(HealthDay News) — Treatment with the selective noradrenalin-reuptake-inhibitor atomoxetine is not associated with increased suicide risk compared with stimulant use in children and adolescents ...